Juba Watts-Cain
Family Medicine · Chicago, ILNPI 1255997516
Payments from drug & device makers
Across 214 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$1K
- Merck$456
- Napo Pharmaceuticals Inc$198
- Novo Nordisk$188
- Johnson & Johnson$126
- plus $548 from 13 others
What the payments were for
- Food & beverage$4,468100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 87 | $1,824 |
| Viiv Healthcare Company | 59 | $1,128 |
| Merck | 18 | $456 |
| Napo Pharmaceuticals Inc | 9 | $198 |
| Novo Nordisk | 8 | $188 |
| Johnson & Johnson(2 entities) | 6 | $126 |
| AbbVie | 5 | $98 |
| Pfizer | 4 | $86 |
| Theratechnologies Inc. | 3 | $85 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Exact Sciences | 2 | $42 |
| Amgen | 2 | $36 |
| EMD Serono, Inc. | 2 | $34 |
| Seqirus USA Inc | 1 | $29 |
| Inspire Medical Systems, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| GSK | 1 | $16 |
| Dynavax Technologies Corporation | 2 | $11 |
How this compares
$4,468 in reported general payments places this provider in the 90th percentile of 4,116 family medicine providers in Illinois.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DescovyEmtricitabine/Tenofov Alafenam | 56 | $149,310 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 31 | $148,841 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 26 | $112,239 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 14 | $88,772 |
| TivicayDolutegravir Sodium | 30 | $78,259 |
| DovatoDolutegravir Sodium/Lamivudine | 20 | $62,681 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 26 | $1,053 |
| Humulin 70-30Insulin Nph Hum/Reg Insulin Hm | 11 | $615 |
| Amlodipine Besylate | 36 | $183 |
| Sertraline Hcl | 11 | $124 |
| Pravastatin Sodium | 12 | $117 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 13 | $97 |
| Metformin Hcl | 19 | $83 |
| Gabapentin | 17 | $66 |
| Acyclovir | 11 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadDescovy, Genvoya, Biktarvy | $1,824 | $410,390113 claims |
| Viiv Healthcare CompanyTivicay, Dovato | $1,128 | $140,94050 claims |
| Lilly USA, LLCHumulin 70-30 | $18 | $61511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Chicago
- Bradley TorphyChicago$3M
- Frank PhillipsChicago$1.6M
- Ayoade AkereChicago$484K
- Sandy GibsonChicago$309K
- Mandy GittlerChicago$204K
- Jacqueline OlivoChicago$165K
- Sameer PanjwaniChicago$136K
- Igor AltmanChicago$64K
- Juan RojasChicago$40K
- Mark SimonChicago$39K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.